about
Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.[SSC International Guideline 2016 - Management of Sepsis and Septic Shock].Increased circulating microRNA-122 is a biomarker for discrimination and risk stratification in patients defined by sepsis-3 criteria.Increased circulating microRNA-122 is associated with mortality and acute liver injury in the acute respiratory distress syndrome.Clinical Frailty Scale (CFS) reliably stratifies octogenarians in German ICUs: a multicentre prospective cohort study.The aquaporin 5 -1364A/C promoter polymorphism impacts on resolution of acute kidney injury in pneumonia evoked ARDSEvaluation of inhaled salbutamol effectiveness under supportive use of electrical impedance tomography in ventilated ICU patients: study protocol for a randomised controlled clinical trialLong-term mortality and outcome in hospital survivors of septic shock, sepsis, and severe infections: The importance of aftercareA pharmacometric approach to define target site-specific breakpoints for bacterial killing and resistance suppression integrating microdialysis, time-kill curves and heteroresistance data: A case study with moxifloxacinAquaporin 5 -1364A/C Promoter Polymorphism Is Associated with Pulmonary Inflammation and Survival in Acute Respiratory Distress SyndromeDNA methylation of a NF-κB binding site in the aquaporin 5 promoter impacts on mortality in sepsisMajor Adverse Kidney Events Are Associated with the Aquaporin 5 -1364A/C Promoter Polymorphism in Sepsis: A Prospective Validation StudyRepeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patientsThe Aquaporin 5 -1364A/C Promoter Polymorphism Is Associated With Cytomegalovirus Infection Risk in Kidney Transplant RecipientsA novel understanding of postoperative complications: In vitro study of the impact of propofol on epigenetic modifications in cholinergic genesThe Aquaporin3 Promoter Polymorphism -1431 A/G is Associated with Acute Graft Rejection and Cytomegalovirus Infection in Kidney Recipients Due to Altered Immune Cell Migration
P50
Q33801234-CBDDC3D4-5692-4D48-9797-89058EA73873Q50095475-40E4EAB2-6C4F-4401-A470-FE600C9C85D3Q54204360-69CF7E2F-B8AD-4F59-926D-3B018896D28EQ55500120-BD703666-3288-4576-B639-819993873DF4Q55647435-1DCA4A05-F32A-4259-B4CE-A9BB16DAFF40Q60046560-00278A02-4569-4974-B8DC-8F220F08252EQ64101400-1854769C-93D5-4EF6-8E70-3C840E256345Q89679313-3FEE54EC-18B0-4DB6-9D31-86787AA776CBQ89844359-B2C1D475-C79D-48CD-A2A0-3D26A2C5BAE8Q91250284-72479455-732D-4D66-B303-5EADF35A9EECQ91768200-774FBE31-3C57-493E-94A9-8D9F5725B369Q91780775-014673EA-A5FD-4A69-99A7-AE46CF8B9F7BQ91828908-2D277F6D-5359-4B1F-BFF6-356B6AB62ADAQ92188941-EC3446BB-69D1-4EF1-92F3-5521BFCA72AEQ92374397-C633E493-A984-4DC0-8063-C58F5B80DC40Q96294498-2E8AFB23-9D83-4004-B900-5E5F501A6006
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tim Rahmel
@ast
Tim Rahmel
@en
Tim Rahmel
@es
Tim Rahmel
@nl
Tim Rahmel
@sl
type
label
Tim Rahmel
@ast
Tim Rahmel
@en
Tim Rahmel
@es
Tim Rahmel
@nl
Tim Rahmel
@sl
prefLabel
Tim Rahmel
@ast
Tim Rahmel
@en
Tim Rahmel
@es
Tim Rahmel
@nl
Tim Rahmel
@sl
P106
P21
P31
P496
0000-0002-7039-6288